Evidence map›Paper›PMID 31056189›Full record

ArticleThe Journal of allergy and clinical immunology2019

Reply.

Michael E Wechsler, Isabelle Pouliquen, Jonathan Steinfeld, Eric S Bradford, MIRRA study team

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in The Journal of allergy and clinical immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Michael E WechslerNational Jewish Health, Denver, Colo. Electronic address: mikewechsler@gmail.com.
Isabelle PouliquenClinical Pharmacology Modelling & Simulation, GlaxoSmithKline, Uxbridge, United Kingdom.
Jonathan SteinfeldClinical Pharmacology Modelling & Simulation, GlaxoSmithKline, Uxbridge, United Kingdom.
Eric S BradfordClinical Pharmacology Modelling & Simulation, GlaxoSmithKline, Uxbridge, United Kingdom.
MIRRA study team

Funding

Anti IL5 and Churg Strauss Syndrome: a double blind, placebo controlled trialU01AI097073 · NIAID · NATIONAL JEWISH HEALTH · PI WECHSLER, MICHAEL E · 2013 to 2016
$5.8M
NIAID NIH HHS U01 AI097073
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Churg-Strauss SyndromeGranulomatosis with PolyangiitisAntibodies, Monoclonal, HumanizedHumansAntibodies, Monoclonal, Humanizedmepolizumab

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.